AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10513507 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 0
Study 7695978 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (5 micrograms/kg/day subcutaneously, days 5 to > 18)
Number of subjects: 13
Study 7695978 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (5 micrograms/kg/day subcutaneously, days 12 to > 18)
Number of subjects: 13
Study 7695978 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (400 mg/m2 intravenous day 1) and Etoposide (100 mg/m2 intravenous days 1 to > 3)
Number of subjects: 13
Study 1710750 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (daily dose 7.5‐10 mg)
Number of subjects: 518
Study 7464561 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (30 g/day)
Number of subjects: 27
Study 7464561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 27
Study 7464561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (in certain patients)
Number of subjects: 27
Study 7464561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Avicel powder)
Number of subjects: 27
Study 31923136 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage open reduction and Pemberton periacetabular osteotomy (PPO)
Number of subjects: 130
Study 31923136 — intervention group
Group type: COMPARATOR
Intervention: Two separate consecutive operations
Number of subjects: 130
Study 31567670 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative approach algorithm
Number of subjects: 29
Study 31567670 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation technique algorithm
Number of subjects: 29
Study 31567670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bearing surface algorithm
Number of subjects: 29
Study 31567670 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP algorithms applied to operative reports from other institutions
Number of subjects: 29
Study 27855489 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to vastus medialis and vastus lateralis muscles
Number of subjects: 16
Study 27855489 — intervention group
Group type: COMPARATOR
Intervention: Sham taping across the same muscle groups
Number of subjects: 16
Study 27855489 — intervention group
Group type: COMPARATOR
Intervention: No taping
Number of subjects: 16
Study 25532912 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 30
Study 25532912 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Number of subjects: 30
Study 25532912 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 24382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly
Number of subjects: 419
Study 24382002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 24382002 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg weekly
Number of subjects: 419
Study 24382002 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide 20 μg daily
Number of subjects: 419
Study 24382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (all doses)
Number of subjects: 419
Study 24382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 419
Study 21881869 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + BCP
Number of subjects: 24
Study 21881869 — intervention group
Group type: COMPARATOR
Intervention: EMD
Number of subjects: 24
Study 20025373 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self‐change (GSC) treatment in group format
Number of subjects: 264
Study 20025373 — intervention group
Group type: COMPARATOR
Intervention: Guided self‐change (GSC) treatment in individual format
Number of subjects: 264
Study 20025373 — intervention group
Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 264
Study 17434635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Amiodarone (600 mg in three divided doses)
Number of subjects: 223
Study 17434635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Amiodarone (5 mg/kg over 30 min followed by 1000 mg over the next 24 h)
Number of subjects: 223
Study 16275380 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick-to-prick testing with fresh apples
Number of subjects: 29
Study 16275380 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden Delicious and Santana cultivars tested with double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 29
Study 16275380 — intervention group
Group type: COMPARATOR
Intervention: Controlled atmosphere storage (2.5% oxygen/1% carbon dioxide)
Number of subjects: 29
Study 11869844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.015 or 0.03 microg/kg per min)
Number of subjects: 261
Study 11869844 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 261
Study 10587915 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instructions and demonstration on breath actuated inhaler technique
Number of subjects: 0
Study 10587915 — intervention group
Group type: COMPARATOR
Intervention: Written instructions only on BAI use
Number of subjects: 0
Study 10587915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 0
Study 7758236 — intervention group
Group type: EXPERIMENTAL
Intervention: Graves' disease patients
Number of subjects: 95
Study 7758236 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 95
Study 7758236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study 1713882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-reduced induction therapy
Number of subjects: 0
Study 1713882 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy
Number of subjects: 0
Study 7377854 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner care
Number of subjects: 132
Study 7377854 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at hospital outpatient clinics
Number of subjects: 132
Study 7377854 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by a senior occupational therapist
Number of subjects: 132
Study 7377854 — intervention group
Group type: COMPARATOR
Intervention: Overall care judged by an independent assessor
Number of subjects: 132
Study 31547798 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-cell stents
Number of subjects: 714
Study 31547798 — intervention group
Group type: COMPARATOR
Intervention: Closed-cell stents
Number of subjects: 714
Study 27696475 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 32
Study 27696475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25960303 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3-month home-based aerobic training program: 4 daily cycling sessions of 10 minutes each at 90% of heart rate at anaerobic threshold)
Number of subjects: 48
Study 25960303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard therapy)
Number of subjects: 48
Study 23361519 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg MPH
Number of subjects: 18
Study 23361519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21487873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfixation of mesh
Number of subjects: 772
Study 19920784 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 12.5 mg/day
Number of subjects: 30
Study 17303706 — intervention group
Group type: EXPERIMENTAL
Intervention: Hvy-Ramp
Number of subjects: 8
Study 17303706 — intervention group
Group type: COMPARATOR
Intervention: Mod-Ramp
Number of subjects: 8
Study 15126749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) anesthesia
Number of subjects: 27
Study 15126749 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N2O)
Number of subjects: 27
Study 11105740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 284
Study 11105740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 284
Study 11105740 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 284
Study 9169252 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocusert Pilo 40
Number of subjects: 3
Study 9169252 — intervention group
Group type: COMPARATOR
Intervention: Intensive pilocarpine regimen
Number of subjects: 3
Study 9169252 — intervention group
Group type: COMPARATOR
Intervention: Low-dose pilocarpine treatment
Number of subjects: 3
Study 1505412 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory health education
Number of subjects: 200
Study 1505412 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 200
Study 6511134 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (2.5 g) administered immediately after the drugs
Number of subjects: 6
Study 6511134 — intervention group
Group type: COMPARATOR
Intervention: Antacid (20 ml of 8.5% magnesium hydroxide)
Number of subjects: 6
Study 30810400 — intervention group
Group type: EXPERIMENTAL
Intervention: Double trigger (GnRH agonist and hCG, 40 and 34 h prior to OPU)
Number of subjects: 33
Study 30810400 — intervention group
Group type: COMPARATOR
Intervention: hCG trigger (36 h before OPU)
Number of subjects: 33
Study 30810400 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist trigger (GnRHag 36 h before OPU and hCG on day of OPU)
Number of subjects: 33
Study 29487991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 94
Study 29487991 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 94
Study 27338470 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight (<18.5 kg/m²)
Number of subjects: 20694
Study 27338470 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (18.5-23.9 kg/m²)
Number of subjects: 20694
Study 27338470 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (24.0-27.9 kg/m²)
Number of subjects: 20694
Study 27338470 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (≥28.0 kg/m²)
Number of subjects: 20694
Study 26068513 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physician contact within 1 month of follow-up
Number of subjects: 847
Study 21859219 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention for nonsuicidal self-harm
Number of subjects: 70
Study 21859219 — intervention group
Group type: COMPARATOR
Intervention: Suicidal self-harm
Number of subjects: 70
Study 20484173 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonol intake (highest quartile)
Number of subjects: 872
Study 20484173 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in IL‐6 concentration during the trial
Number of subjects: 872
Study 20484173 — intervention group
Group type: EXPERIMENTAL
Intervention: Above median flavonol intake with equal or below median IL‐6 change after baseline
Number of subjects: 872
Study 18779774 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 600 mg/day
Number of subjects: 532
Study 18779774 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day
Number of subjects: 532
Study 18779774 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine XR 800 mg/day
Number of subjects: 532
Study 18779774 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine IR 300 mg/day
Number of subjects: 532
Study 18779774 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine IR 600 mg/day
Number of subjects: 532
Study 18779774 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 532
Study 15967972 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine 4% cream
Number of subjects: 142
Study 15967972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 14601012 — intervention group
Group type: EXPERIMENTAL
Intervention: New procedure for estimating treatment effects
Number of subjects: 0
Study 14601012 — intervention group
Group type: COMPARATOR
Intervention: Conventional procedure for estimating treatment effects
Number of subjects: 0
Study 10231040 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin daily
Number of subjects: 298
Study 10231040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 8915811 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 45
Study 8915811 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 45
Study 1681265 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonston‐Zagreb high‐titre (EZ‐HT) vaccine at 5 months
Number of subjects: 1015
Study 1681265 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwarz high‐titre (SW‐HT) vaccine at 5 months
Number of subjects: 1015
Study 1681265 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by standard low‐titre Schwarz vaccine at 10 months (standard)
Number of subjects: 1015
Study 366539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 366539 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge food materials
Number of subjects: 9
Study 366539 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 9
Study 31761946 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt supplementation (100 mmol NaCl/24h)
Number of subjects: 22
Study 31761946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31097853 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mL of 0.25%)
Number of subjects: 99
Study 31097853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (100 mg)
Number of subjects: 99
Study 31097853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 cc distilled water)
Number of subjects: 99
Study 27981268 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total toothpaste (triclosan/copolymer/fluoride)
Number of subjects: 50
Study 27981268 — intervention group
Group type: COMPARATOR
Intervention: Colgate Herbal toothpaste (0.243% sodium fluoride)
Number of subjects: 50
Study 26138521 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Limberg flap transposition
Number of subjects: 100
Study 26138521 — intervention group
Group type: COMPARATOR
Intervention: Lateral advancement flap transposition with Burow's triangle
Number of subjects: 100
Study 24189212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure ventilation (BV)
Number of subjects: 10
Study 24189212 — intervention group
Group type: COMPARATOR
Intervention: Sham ventilation
Number of subjects: 10
Study 21576658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice a day
Number of subjects: 18113
Study 21576658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice a day
Number of subjects: 18113
Study 21576658 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 18113
Study 19124650 — intervention group
Group type: EXPERIMENTAL
Intervention: Print referencing style during storybook reading sessions (120 sessions over 30 weeks)
Number of subjects: 106
Study 19124650 — intervention group
Group type: COMPARATOR
Intervention: Normal reading style (comparison group)
Number of subjects: 106
Study 15716561 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited treatment of sexual partners
Number of subjects: 1860
Study 15716561 — intervention group
Group type: COMPARATOR
Intervention: Standard partner referral
Number of subjects: 1860
Study 15716561 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited treatment of sexual partners (gonorrhea)
Number of subjects: 1860
Study 15716561 — intervention group
Group type: COMPARATOR
Intervention: Standard partner referral (gonorrhea)
Number of subjects: 1860
Study 15716561 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited treatment of sexual partners (chlamydial infection)
Number of subjects: 1860
Study 15716561 — intervention group
Group type: COMPARATOR
Intervention: Standard partner referral (chlamydial infection)
Number of subjects: 1860
Study 12881083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 100 micrograms every 4 hours (max 500 micrograms)
Number of subjects: 0
Study 12881083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone 6 mg every 6 hours (max 24 mg)
Number of subjects: 0
Study 12881083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal glyceryl trinitrate 500 micrograms every 6 hours (max 2.5 mg)
Number of subjects: 0
Study 10437864 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunisation with paternal mononuclear cells (treatment)
Number of subjects: 183
Study 10437864 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 183
Study 8848700 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT2-receptor antagonist ketanserine
Number of subjects: 13
Study 8848700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2229452 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 19
Study 358757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque 260
Number of subjects: 0
Study 358757 — intervention group
Group type: COMPARATOR
Intervention: Isopaque 260
Number of subjects: 0
Study 29611536 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium medical ozone (40 μg/ml)
Number of subjects: 80
Study 29611536 — intervention group
Group type: EXPERIMENTAL
Intervention: Low medical ozone (20 μg/ml)
Number of subjects: 80
Study 29611536 — intervention group
Group type: EXPERIMENTAL
Intervention: High medical ozone (60 μg/ml)
Number of subjects: 80
Study 29611536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 27829455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 443
Study 27829455 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary case management)
Number of subjects: 443
Study 23911196 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg weekly (Taspo10)
Number of subjects: 148
Study 23911196 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg weekly (Taspo20)
Number of subjects: 148
Study 23911196 — intervention group
Group type: COMPARATOR
Intervention: Exenatide 10 mcg BID (Exe)
Number of subjects: 148
Study 22726466 — intervention group
Group type: EXPERIMENTAL
Intervention: New stent
Number of subjects: 80
Study 22726466 — intervention group
Group type: COMPARATOR
Intervention: Conventional stent
Number of subjects: 80
Study 19679600 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 154
Study 19679600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 19172548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal testosterone 7.6mg, 15.2mg, or 22.8mg (single dose)
Number of subjects: 29
Study 19172548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal testosterone 7.6mg (twice or three times a day)
Number of subjects: 29
Study 19172548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal testosterone (all doses)
Number of subjects: 29
Study 16275194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 20
Study 16275194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12161829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular stimulation of the quadriceps muscle
Number of subjects: 24
Study 12161829 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation of the quadriceps muscle
Number of subjects: 24
Study 9951570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 10
Study 9951570 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic adrenocorticotropic hormone (ACTH)
Number of subjects: 10
Study 9951570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7811163 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC‐PC (combined algorithm)
Number of subjects: 375
Study 7811163 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC‐P (parent information only)
Number of subjects: 375
Study 7811163 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC‐C (child information only)
Number of subjects: 375
Study 7811163 — intervention group
Group type: COMPARATOR
Intervention: Community sample
Number of subjects: 375
Study 2190461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray 1.25 mg
Number of subjects: 12
Study 2190461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray 2.5 mg
Number of subjects: 12
Study 2190461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray 5.0 mg
Number of subjects: 12
Study 2190461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 378754 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg daily, 5 days a week
Number of subjects: 43
Study 378754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 378754 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 43
Study 30950691 — intervention group
Group type: COMPARATOR
Intervention: native‐accented (Midland American English) speech
Number of subjects: 120
Study 30950691 — intervention group
Group type: EXPERIMENTAL
Intervention: nonnative‐accented (Spanish‐ and Japanese‐accented English) speech
Number of subjects: 120
Study 29135865 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone administered intravenously before cochlear implantation
Number of subjects: 74
Study 29135865 — intervention group
Group type: COMPARATOR
Intervention: No steroid administration (control group)
Number of subjects: 74
Study 29135865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients exhibiting spikes
Number of subjects: 74
Study 29135865 — intervention group
Group type: COMPARATOR
Intervention: Steroid administration
Number of subjects: 74
Study 25371029 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 60
Study 25371029 — intervention group
Group type: COMPARATOR
Intervention: Sham laser (control)
Number of subjects: 60
Study 24368465 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 61
Study 24368465 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 61
Study 21767798 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 14